PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian healthcare sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, cementing its position as a leading player in the plasma fractionation industry. With this funding, PlasmaGen has now raised over ₹600 crore to date, demonstrating the confidence of investors in its mission and capabilities.
PlasmaGen Biosciences is a pioneering company in India’s plasma fractionation sector, operating one of the country’s five plasma fractionation facilities near Bengaluru. The company’s state-of-the-art facility is equipped with cutting-edge technology, enabling it to produce high-quality plasma-derived products that cater to the growing demand for life-saving therapies. PlasmaGen’s products are used to treat a range of diseases, including bleeding disorders, immune deficiencies, and infectious diseases, making it a vital contributor to the country’s healthcare ecosystem.
The funding round was led by ViNS Bioproducts, a company with a strong track record of investing in innovative healthcare ventures. PlasmaGen is also backed by prominent investors, including Eight Roads, FIL Capital, and F-Prime, which have been supporting the company’s growth and expansion plans. The involvement of these esteemed investors is a testament to PlasmaGen’s potential and the vast opportunities that exist in India’s plasma fractionation market.
The Indian plasma fractionation industry has been gaining momentum in recent years, driven by the increasing demand for plasma-derived products and the government’s initiatives to promote the development of the sector. The industry is expected to grow significantly, driven by factors such as the rising prevalence of diseases, the expanding healthcare infrastructure, and the growing awareness about the importance of plasma-derived therapies.
PlasmaGen is well-positioned to capitalize on this growth, with its world-class facility, experienced management team, and strong distribution network. The company has established partnerships with leading hospitals, research institutions, and pharmaceutical companies, enabling it to stay at the forefront of innovation and customer needs. With the latest funding, PlasmaGen plans to further expand its operations, enhance its product portfolio, and strengthen its market presence, both in India and globally.
The company’s commitment to quality, safety, and innovation has earned it numerous accolades and certifications, including ISO 9001:2015 and WHO GMP. PlasmaGen’s dedication to excellence has also led to the development of a robust research and development pipeline, with several new products in various stages of development. These products are expected to address significant unmet medical needs, further solidifying PlasmaGen’s position as a leader in the plasma fractionation industry.
The funding raised by PlasmaGen is a significant milestone for the Indian healthcare sector, highlighting the potential for innovation and growth in the country. It also underscores the importance of investments in healthcare infrastructure, research, and development, which are critical to addressing the country’s healthcare challenges. As the Indian healthcare sector continues to evolve, companies like PlasmaGen are expected to play a vital role in shaping the industry’s future, driving innovation, and improving patient outcomes.
In conclusion, PlasmaGen’s ₹150 crore funding round is a remarkable achievement, demonstrating the company’s potential and the confidence of investors in its mission. With a valuation of over ₹1,500 crore, PlasmaGen is poised to become a leading player in the global plasma fractionation industry. As the company continues to expand its operations, enhance its product portfolio, and strengthen its market presence, it is expected to make a significant impact on the lives of patients, both in India and globally.
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
